Cargando…
Autoantibodies Neutralizing Type I INFs May Be Associated with Efficacy of Tocilizumab in COVID-19 Pneumonia
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177133/ https://www.ncbi.nlm.nih.gov/pubmed/35676568 http://dx.doi.org/10.1007/s10875-022-01295-5 |
| _version_ | 1784722825638051840 |
|---|---|
| author | Chauvineau-Grenier, Angélique Bastard, Paul Casanova, Jean-Laurent Rossi, Benjamin |
| author_facet | Chauvineau-Grenier, Angélique Bastard, Paul Casanova, Jean-Laurent Rossi, Benjamin |
| author_sort | Chauvineau-Grenier, Angélique |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9177133 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Springer US |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-91771332022-06-09 Autoantibodies Neutralizing Type I INFs May Be Associated with Efficacy of Tocilizumab in COVID-19 Pneumonia Chauvineau-Grenier, Angélique Bastard, Paul Casanova, Jean-Laurent Rossi, Benjamin J Clin Immunol Letter to Editor Springer US 2022-06-08 2022 /pmc/articles/PMC9177133/ /pubmed/35676568 http://dx.doi.org/10.1007/s10875-022-01295-5 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Letter to Editor Chauvineau-Grenier, Angélique Bastard, Paul Casanova, Jean-Laurent Rossi, Benjamin Autoantibodies Neutralizing Type I INFs May Be Associated with Efficacy of Tocilizumab in COVID-19 Pneumonia |
| title | Autoantibodies Neutralizing Type I INFs May Be Associated with Efficacy of Tocilizumab in COVID-19 Pneumonia |
| title_full | Autoantibodies Neutralizing Type I INFs May Be Associated with Efficacy of Tocilizumab in COVID-19 Pneumonia |
| title_fullStr | Autoantibodies Neutralizing Type I INFs May Be Associated with Efficacy of Tocilizumab in COVID-19 Pneumonia |
| title_full_unstemmed | Autoantibodies Neutralizing Type I INFs May Be Associated with Efficacy of Tocilizumab in COVID-19 Pneumonia |
| title_short | Autoantibodies Neutralizing Type I INFs May Be Associated with Efficacy of Tocilizumab in COVID-19 Pneumonia |
| title_sort | autoantibodies neutralizing type i infs may be associated with efficacy of tocilizumab in covid-19 pneumonia |
| topic | Letter to Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177133/ https://www.ncbi.nlm.nih.gov/pubmed/35676568 http://dx.doi.org/10.1007/s10875-022-01295-5 |
| work_keys_str_mv | AT chauvineaugrenierangelique autoantibodiesneutralizingtypeiinfsmaybeassociatedwithefficacyoftocilizumabincovid19pneumonia AT bastardpaul autoantibodiesneutralizingtypeiinfsmaybeassociatedwithefficacyoftocilizumabincovid19pneumonia AT casanovajeanlaurent autoantibodiesneutralizingtypeiinfsmaybeassociatedwithefficacyoftocilizumabincovid19pneumonia AT rossibenjamin autoantibodiesneutralizingtypeiinfsmaybeassociatedwithefficacyoftocilizumabincovid19pneumonia |